Paolo Prandoni

Learn More
BACKGROUND AND OBJECTIVE Rivaroxaban is an oral, direct Factor Xa inhibitor, which is at an advanced stage of clinical development for prevention and treatment of thromboembolic disorders. Two phase(More)